These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 37439350)

  • 1. The Potential of Psychedelics for the Treatment of Episodic Migraine.
    Schindler EAD
    Curr Pain Headache Rep; 2023 Sep; 27(9):489-495. PubMed ID: 37540398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Resurgence of Hallucinogen Drugs in Clinical Research.
    Rivera-García MT; Cruz SL
    Rev Invest Clin; 2023; 75(3):169-178. PubMed ID: 37441761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. This is your brain on death: a comparative analysis of a near-death experience and subsequent 5-Methoxy-DMT experience.
    Michael P; Luke D; Robinson O
    Front Psychol; 2023; 14():1083361. PubMed ID: 37457069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia.
    Mamat R; Rashid RA; Shin SM; Ibrahim B; Wahab S; Ahmad A
    J Addict Dis; 2023 Aug; ():1-13. PubMed ID: 37540000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the mushrooming reports of "quiet quitting": Employees' lifetime psilocybin use predicts their overtime hours worked.
    Korman BA
    J Psychoactive Drugs; 2024; 56(4):475-484. PubMed ID: 37525416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: Psychedelic-induced seizures captured by intracranial electrocorticography.
    Blond BN; Schindler EAD
    Front Neurol; 2023; 14():1214969. PubMed ID: 37456653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confronting the figure of the "mad scientist" in psychedelic history: LSD's use as a correctional tool in the postwar period.
    Jones A
    Front Psychol; 2023; 14():1129428. PubMed ID: 37519357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between the default mode network and the theory of mind network as revealed by psychedelics - A meta-analysis.
    Soares C; Gonzalo G; Castelhano J; Castelo-Branco M
    Neurosci Biobehav Rev; 2023 Sep; 152():105325. PubMed ID: 37467907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical student attitudes and perceptions of psychedelic-assisted therapies.
    Li I; Fong R; Hagen M; Tabaac B
    Front Psychiatry; 2023; 14():1190507. PubMed ID: 37441143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of psychedelics for the treatment of Alzheimer's disease and related dementias.
    Winkelman MJ; Szabo A; Frecska E
    Eur Neuropsychopharmacol; 2023 Nov; 76():3-16. PubMed ID: 37451163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS.
    Castillo A; Dubois J; Field RM; Fishburn F; Gundran A; Ho WC; Jawhar S; Kates-Harbeck J; M Aghajan Z; Miller N; Perdue KL; Phillips J; Ryan WC; Shafiei M; Scholkmann F; Taylor M
    Sci Rep; 2023 Jul; 13(1):11665. PubMed ID: 37468572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.
    Jahanabadi S; Amiri S; Karkeh-Abadi M; Razmi A
    Fitoterapia; 2023 Sep; 169():105620. PubMed ID: 37490982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada.
    Glynos NG; Kruger DJ; Kolbman N; Boehnke K; Lucas P
    J Psychoactive Drugs; 2023; 55(5):660-671. PubMed ID: 37516904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol.
    Lear MK; Smith SM; Pilecki B; Stauffer CS; Luoma JB
    Front Psychiatry; 2023; 14():1083354. PubMed ID: 37520237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rundel, Megan. (2022). "Psychedelic psychoanalysis: Transformations of the Self." Psychoanalytic Dialogues, 32(5), 469-483. Published online: November 7, 2022. https://doi.org/10.1080/10481885.2022.2106139.
    Berg M
    J Anal Psychol; 2023 Sep; 68(4):789-792. PubMed ID: 37522154
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.
    Simonsson O; Carlbring P; Carhart-Harris R; Davis AK; Nutt DJ; Griffiths RR; Erritzoe D; Goldberg SB
    Psychiatry Res; 2023 Sep; 327():115349. PubMed ID: 37523886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective Connectivity of Thalamocortical Interactions Following d-Amphetamine, LSD, and MDMA Administration.
    Avram M; Müller F; Preller KH; Razi A; Rogg H; Korda A; Holze F; Vizeli P; Ley L; Liechti ME; Borgwardt S
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):522-532. PubMed ID: 37532129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to: Marketing pitches of 'magic mushrooms' and 'psychedelics' mask that psychotomimetics use exposes those vulnerable to serious adverse effects.
    Morton E; Sakai K; Ashtari A; Pleet M; Michalak EE; Woolley J
    J Psychopharmacol; 2023 Jul; 37(7):750-751. PubMed ID: 37439350
    [No Abstract]   [Full Text] [Related]  

  • 19. Marketing pitches of 'magic mushrooms' and 'psychedelics' mask that psychotomimetics use exposes those vulnerable to serious adverse effects.
    Braillon A; Naudet F
    J Psychopharmacol; 2023 Jul; 37(7):749-750. PubMed ID: 37132539
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.